Feature | May 24, 2013

InspireMD's MGuard Embolic Protection Stent Shows Lower Mortality Rate in STEMI

The six-month trial looked at 433 patients with STEMI

mGuard stent, STEMI

May 24, 2013 — InspireMD Inc. announced new six-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-cause mortality in ST-segment elevation myocardial infarction (STEMI) patients. With its micro-net mesh sleeve, MGuard EPS prevents unstable arterial plaque and thrombus (clots) that cause heart attack blockage from breaking off and exacerbating damage.

The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60 to 90 minutes post-procedure (a strong predictor of mortality). Secondary endpoint clinical outcomes continue to show a lower mortality rate with MGuard EPS compared to control (0.5 percent vs. 2.8 percent, P=0.06) at six months. These findings corroborate the previously announced 30-day results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug-eluting stents used as a control (0 percent vs. 1.9 percent, P=0.06).  

In the MASTER trial, a total of 433 patients with STEMI presenting within 12 hours of symptom onset undergoing percutaneous coronary intervention (PCI) were randomized at 50 sites in nine countries to the MGuard EPS (n = 217) or commercially available bare metal or drug-eluting stents (n = 216).

Watch the video on InspireMD’s Micronet Technology at www.youtube.com/watch?v=EbrhcQMM7YE.

For more information: www.InspireMD.com

Related Content

PFO occluder, amplatzer
Feature | Structural Heart Occluders| May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
radial access, transradial
Feature | Radial Access| May 27, 2016 | Dave Fornell
The use of transradial artery vascular access for percutaneous coronary intervention (PCI) in the United States has s
Ambio Health telemonitoring system, LifeBridge Health Cardiovascular Institute, Baltimore, pilot study
News | Remote Monitoring| May 26, 2016
The LifeBridge Health Cardiovascular Institute, Baltimore, has launched a pilot study to evaluate the potential...
Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
cath lab, radiation exposure, glocoma
Feature | Radiation Dose Management| May 26, 2016 | Dave Fornell
May 27, 2016 — Radiation exposure to cath lab staff and physicians has seen growing concern in recent years, as the p
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Overlay Init